FIELD: immunology.
SUBSTANCE: disclosed is a method for producing primary T-cells, involving genetic modification of T-cells using low-boiling endonucleases, particularly TALE-nuclease, capable of selectively inactivating a gene, which encodes an immune control point protein, and a gene which codes a T-cell receptor component (TCR), and introduction into T-cells of a nucleic acid coding a chimeric antigenic antigen receptor to CD19. What is described is a T cell obtained in such a way, containing it a pharmaceutical composition and a method of treating cancer.
EFFECT: present invention can be used in adoptive immunotherapy.
17 cl, 31 dwg, 15 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR CONSTRUCTING ALLOGENIC AND HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2736616C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR IMPROVED IMMUNE CELL THERAPY | 2018 |
|
RU2797304C2 |
| IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING ANTIGEN PRESENT SIMULTANEOUSLY ON IMMUNE CELLS AND ON PATHOLOGICAL CELLS | 2015 |
|
RU2714258C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF HOMING-ENDONUCLEASE PD-1 | 2017 |
|
RU2781083C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF ENDONUCLEASE CBLB | 2018 |
|
RU2779097C2 |
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
